Efficacy and safety of Metoprolol Succinate prolonged-release tablet in patients with mild to moderate hypertension
Study identifier:D4025L00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open-label, non-comparative, multi-centre study to evaluate the Efficacy and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with mild to moderate essential hypertension
Medical condition
hypertension
Phase
Phase 4
Healthy volunteers
No
Study drug
metoprolol succinate prolonged-release tablet and felodipine
Sex
All
Actual Enrollment
310
Study type
Interventional
Age
18 Years - 70 Years
Date
Study Start Date: 01 Oct 2005
Primary Completion Date: 01 Apr 2006
Study Completion Date: 01 May 2006
Study design
Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 The patients with mild to moderate essential hypertension | Drug: metoprolol succinate prolonged-release tablet and felodipine a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally Other Name: Betaloc ZOK and Plendil |
Contacts
Investigators
Principal Investigator
Lisheng Liu
BeiJing Hypertension League
